SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.400+1.7%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: luckydog888/14/2025 8:43:50 AM
2 Recommendations

Recommended By
erippetoe
waitwatchwander

   of 1216
 
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target
BENZINGA

Aug-14-2025 8:35 a.m. ET

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (IBRX) with a Buy and maintains $24 price target.

And I thought his price target all this time was $30 ............... :)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News